SBL
GILD icon

Sargent Bickham Lagudis’s Gilead Sciences GILD Stock Holding History

Sargent Bickham Lagudis’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$231K Hold
2,692
– – 0.02% 253
2022
Q3 		$166K Sell
2,692
-344
-11% -$21.7K 0.01% 259
2022
Q2 		$188K Buy
3,036
+344
+13% +$21.3K 0.02% 256
2022
Q1 		$160K Sell
2,692
-655
-20% -$41.9K 0.01% 274
2021
Q4 		$243K Sell
3,347
-195
-6% -$13.4K 0.02% 227
2021
Q3 		$247K Sell
3,542
-4,469
-56% -$314K 0.02% 224
2021
Q2 		$552K Buy
8,011
+949
+13% +$63.4K 0.05% 161
2021
Q1 		$456K Buy
7,062
+1,231
+21% +$79.4K 0.04% 168
2020
Q4 		$340K Buy
5,831
+971
+20% +$58.6K 0.03% 186
2020
Q3 		$307K Buy
4,860
+514
+12% +$35.6K 0.03% 177
2020
Q2 		$334K Sell
4,346
-188
-4% -$14.4K 0.04% 165
2020
Q1 		$339K Buy
4,534
+169
+4% +$11.7K 0.04% 162
2019
Q4 		$284K Buy
4,365
+33
+0.8% +$2.15K 0.03% 174
2019
Q3 		$275K Sell
4,332
-109
-2% -$7.13K 0.03% 170
2019
Q2 		$300K Sell
4,441
-288
-6% -$18.9K 0.04% 176
2019
Q1 		$307K Buy
4,729
+114
+2% +$7.58K 0.04% 182
2018
Q4 		$289K Sell
4,615
-191
-4% -$13.3K 0.04% 172
2018
Q3 		$371K Buy
4,806
+718
+18% +$54.2K 0.04% 160
2018
Q2 		$290K Buy
4,088
+328
+9% +$23.2K 0.04% 167
2018
Q1 		$283K Sell
3,760
-50
-1% -$3.98K 0.04% 170
2017
Q4 		$273K Buy
3,810
+1,187
+45% +$90.1K 0.03% 187
2017
Q3 		$213K Buy
2,623
+5
+0.2% +$382 0.03% 210
2017
Q2 		$185K Buy
2,618
+6
+0.2% +$399 0.02% 211
2017
Q1 		$177K Sell
2,612
-519
-17% -$36.5K 0.02% 221
2016
Q4 		$224K Sell
3,131
-178
-5% -$13.2K 0.03% 190
2016
Q3 		$262 Buy
3,309
+100
+3% +$8.12K 0.04% 180
2016
Q2 		$268K Buy
3,209
+79
+3% +$7.01K 0.04% 174
2016
Q1 		$287K Buy
+3,130
New +$282K 0.05% 171

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sargent Bickham Lagudis's GILD Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Gilead Sciences (GILD) position steady in Q4 2022 at 2,692 shares worth $231K. The position accounts for 0.02% of the portfolio, ranked #253.

Sargent Bickham Lagudis first reported a position in GILD in Q1 2016 and has held it in 28 quarters since. The position peaked at $552K in Q2 2021. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

  • Sargent Bickham Lagudis held 2,692 shares of Gilead Sciences worth $231K as of Q4 2022.
  • Sargent Bickham Lagudis left its Gilead Sciences share count unchanged in Q4 2022.
  • Gilead Sciences made up 0.02% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #253 holding.
  • Sargent Bickham Lagudis first reported a position in Gilead Sciences in Q1 2016 and has held it in 28 quarters since.
  • Sargent Bickham Lagudis's Gilead Sciences position peaked at $552K in Q2 2021.
  • 1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.